OSR (NASDAQ:OSRH) Stock Price Down 5.5% – Should You Sell?

OSR Holdings, Inc. (NASDAQ:OSRH)’s share price fell 5.5% during mid-day trading on Tuesday . The company traded as low as $0.4253 and last traded at $0.4375. Approximately 579,919 shares changed hands during mid-day trading, a decline of 28% from the average session volume of 803,054 shares. The stock had previously closed at $0.4628.

Analyst Ratings Changes

OSRH has been the subject of several research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of OSR in a research note on Wednesday, June 24th. Wall Street Zen raised shares of OSR from a “strong sell” rating to a “sell” rating in a research report on Saturday, April 25th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has an average rating of “Sell”.

OSR Stock Performance

The company has a market cap of $15.37 million, a P/E ratio of -1.33 and a beta of 0.72. The business’s 50-day moving average price is $0.41 and its 200 day moving average price is $0.50.

OSR (NASDAQ:OSRH) last issued its earnings results on Wednesday, May 13th. The company reported ($0.09) earnings per share (EPS) for the quarter. OSR had a negative net margin of 363.26% and a negative return on equity of 7.24%. The firm had revenue of $0.48 million during the quarter.

Institutional Investors Weigh In On OSR

A hedge fund recently bought a new position in OSR stock. Susquehanna International Group LLP acquired a new position in shares of OSR Holdings, Inc. (NASDAQ:OSRH) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 79,807 shares of the company’s stock, valued at approximately $43,000. Susquehanna International Group LLP owned 0.37% of OSR at the end of the most recent reporting period. 55.30% of the stock is owned by institutional investors.

About OSR

OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D “platform technologies” versus “assets only” companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials.